Ligand Pharmaceuticals Inc 8-K Filing
Ticker: LGNZZ · Form: 8-K · Filed: Nov 6, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ligand Pharmaceuticals Inc (ticker: LGNZZ) to the SEC on Nov 6, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market).
How long is this filing?
Ligand Pharmaceuticals Inc's 8-K filing is 2 pages with approximately 512 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-11-06 07:08:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market
Filing Documents
- lgnd-20251106.htm (8-K) — 25KB
- q32025earningsrelease_ex991.htm (EX-99.1) — 243KB
- newligandlogo.jpg (GRAPHIC) — 11KB
- 0000886163-25-000058.txt ( ) — 422KB
- lgnd-20251106.xsd (EX-101.SCH) — 2KB
- lgnd-20251106_lab.xml (EX-101.LAB) — 21KB
- lgnd-20251106_pre.xml (EX-101.PRE) — 12KB
- lgnd-20251106_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Ligand Pharmaceuticals Incorporated (the "Company") issued a press release announcing its financial results for the three and nine months ended September 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated November 6, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: November 6, 2025 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary